Our current findings are in agreement with the observation that JNK is pro-tumorigenic since we demonstrate that inhibition of JNK with SP600126 in HER2-positive cells that are resistant to trastuzumab and lapatinib, impairs tumor growth. Here, ERBB2 is linked to neoplasm.